NCT04730232Unknown2 期
An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Tianjin Medical University Second Hospital1 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2020年12月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 63
- 试验地点
- 1
- 主要终点
- Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel
研究概览
简要总结
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent;
- •Ability to comply with the protocol;
- •Age ≥ 18 years;
- •High-risk non-muscle-invasive urothelial carcinoma or high-risk non-muscle-invasive urothelial carcinoma as the main pathological component > 50%, difined as following:
- •a. T1 b. High-grade Ta c.Carcinoma in situ(CIS);
- •Multi-point biopsy of bladder shows there are more than 2 section and over 3 points of pathological specimens are diagnosed as above, meanwhile, the tumor has to be diagnosed as not completely resectable by at least 2 senior urologist;
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;
- •Agreed to provide tissue examination samples (for detection of PD-L1 expression, tumor mutation load, IHC, detection of DNA and RNA, etc;)
- •Organ function level must meet the following requirements:
- •Hematological indexes: neutrophil count >= 1.5x10^9/L, platelet count >= 80x10^9/L, hemoglobin >= 6.0 g/dl (can be maintained by blood transfusion);
- •Liver function: total bilirubin <=1.5 ULN, alanine aminotransferase and aspartate aminotransferase <=2.5 ULN;
- •The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up;
排除标准
- •Receive live attenuated vaccine within 4 weeks before treatment or during the study period;
- •Active, known or suspected autoimmune diseases;
- •History of primary immunodeficiency;
- •Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
- •Pregnant or lactating female patients;
- •Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions;
- •Prior use of immunosuppressive drugs within 4 weeks prior to the start of treatment, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with the same physiological dose);
- •Known or suspected allergy to tislelizumab and albumin paclitaxel;
- •Have a clear history of active tuberculosis;
- •Received PD-1 / PD-L1 / CTLA-4 antibody or other immunotherapy in the past;
- •Participating in other clinical researchers;
- •Men with reproductive capacity or women who are likely to become pregnant do not take reliable contraceptive measures;
- •Uncontrolled concurrent diseases, including but not limited to:
- •HIV infected (HIV antibody positive);
- •Severe infection in active stage or poorly controlled;
- •Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [i.e. hypertension greater than or equal to CTCAE grade 2 after drug treatment]);
- •Patients with active bleeding or new thrombotic disease.
研究组 & 干预措施
Tislelizumab and Nab-Paclitaxel
Experimental
Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
干预措施: Tislelizumab (Drug)
Tislelizumab and Nab-Paclitaxel
Experimental
Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
干预措施: Nab-paclitaxel (Drug)
结局指标
主要结局
Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel
时间窗: At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of tislelizumab)
次要结局
- Number of adverse events and severity by grade (CTCAE)(12 weeks of treatment plus 30 days for toxicity followup)
- Cystectomy-Free Survival (CFS)(up to 3 years)
- Duration of Response (DOR)(up to 3 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center StudyHigh-Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNCT05418309Tianjin Medical University Second Hospital63
进行中（未招募）
2 期
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaMuscle Invasive Bladder CancerUrothelial CarcinomaNCT04730219Tianjin Medical University Second Hospital48
进行中（未招募）
2 期
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRCColorectal NeoplasmsNCT05143099Shanghai Zhongshan Hospital35
招募中
2 期
Tislelizumab Plus Lenvatinib in Stage III-IV RCCAdvanced Kidney CancerNCT05485883Tianjin Medical University Second Hospital20
Unknown
1 期
Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung CancerNon-Small Cell Lung CancerNCT05273814Tianjin Medical University Cancer Institute and Hospital30